Recent evidence has demonstrated the advantages of using BRAF-targeted therapies, either alone or in combination with MEK inhibition and epidermal growth factor receptor-targeted treatment, in patients diagnosed with advanced colorectal cancer carrying the BRAF V600E mutation [74]. The gene discussed is EGFR; the disease is colorectal cancer.